Aligos ALG-000184 Chronic Hepatitis B Phase 1 Study Results

Clinical study results for Aligos' investigational capsid assembly modulator ALG-000184 combined with entecavir in treatment of chronic hepatitis B. Presents data from a Phase 1 randomized, double-blind trial showing dose-dependent reductions in HBsAg levels in HBeAg+ subjects treated for over 12 weeks.